CYP24A1 and Hypercalcemia: However, some factors may limit the usefulness of active vitamin D or vitamin D analogue therapy, such as the resultant hypercalcemia and the inappropriately high levels of CYP24A1 activity, which, besides the deactivation of 1,25(OH)2D3, also have the potential to deactivate vitamin D analogues [19].